Skip to main content
SpringerLink
Log in

Complex Challenges of Pulmonary Hypertension

  • Chapter
  • First Online:
Scleroderma

Abstract

It is now well appreciated that pulmonary hypertension is a frequent complication of scleroderma and that it occurs in both of the major disease subsets. However, despite a much greater understanding of the different forms of pulmonary hypertension and the availability of effective treatments for different forms of this disease, it remains one of the most feared complications of scleroderma. Compared with other forms of PAH that occur in scleroderma has a significantly worse outcome, and this is especially in comparison with idiopathic PAH. Thus, the strategies that are used for PAH may need to be modified in the context of scleroderma, and this is discussed below.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493–537.

    Article  PubMed  Google Scholar 

  2. Badesch BD, Champion HC, Gomez-Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55–6.

    Article  PubMed  Google Scholar 

  3. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. Eur Respir J. 2009. doi:10.1183/09031936.00145608.

  4. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179(2):151–7.

    Article  PubMed  Google Scholar 

  5. Tolle JJ MD1, Waxman AB MD, PhD1, Van Horn TL BA1, et al. Exercise-induced pulmonary arterial hypertension. Circulation. 2008;118(21):2183–9.

    Article  PubMed  Google Scholar 

  6. Doyle AE, Goodwin JF, Harrison CV, Steiner RE. Pulmonary vascular patterns in pulmonary hypertension. Br Heart J. 1957;19(3):353–65.

    Article  PubMed  CAS  Google Scholar 

  7. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134:44–54.

    Article  PubMed  CAS  Google Scholar 

  8. Shah MR, Stinnett SS, McNulty SE, et al. Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. Am Heart J. 2001;141:908.

    Article  PubMed  CAS  Google Scholar 

  9. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 2002;85(2–3):195–7.

    Article  PubMed  Google Scholar 

  10. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelinA receptor antagonist trial in heart failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):347–54.

    Article  PubMed  CAS  Google Scholar 

  11. Ghio S, Gavazzi A, Campana C, et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001;37:183.

    Article  PubMed  CAS  Google Scholar 

  12. Phosphodiesterase-5 (PDE5) inhibition and pulmonary hypertension in diastolic Heart Failure Clinicaltrials.gov identifier NCT01156636.

    Google Scholar 

  13. A study to test the effects of Riociguat in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction (DILATE) Clinicaltrials.gov identifier NCT01172756.

    Google Scholar 

  14. Torre-Amione G MD, PhD, Southard RE MD, Loebe MM, et al. Reversal of secondary pulmonary hypertension by axial and pulsatile mechanical circulatory support. J Heart Lung Transplant. 2010;29:195–200.

    Article  PubMed  Google Scholar 

  15. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377(9766):658–66.

    Article  PubMed  Google Scholar 

  16. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:189–94.

    Article  PubMed  Google Scholar 

  17. Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–52.

    Article  PubMed  Google Scholar 

  18. Nihtyanova SI, Tang EC, Coghlan JG, et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. Q J Math. 2010;103(2):109–15.

    CAS  Google Scholar 

  19. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–30.

    Article  PubMed  Google Scholar 

  20. Dorfmüller P, Humbert M, Fet P, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol. 2007;38:893–902.

    Article  PubMed  Google Scholar 

  21. O’Callaghan DS, Dorfmuller P, Jaïs X, et al. Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? Presse Med. 2011;40(1 Pt 2):e65–78.

    PubMed  Google Scholar 

  22. Mukerjee D, StGeorge St D, Coleiro B, et al. Prevalence & outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088–93.

    Article  PubMed  CAS  Google Scholar 

  23. Sitbon O, Humbert M, Ioos V, et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? [abstract]. Am J Respir Crit Care Med. 2003;167:A440.

    Google Scholar 

  24. Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J. 2006;28:999–1004.

    Article  PubMed  CAS  Google Scholar 

  25. Sanchez O, Sitbon O, Jaïs X, et al. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130(1):182–9.

    Article  PubMed  CAS  Google Scholar 

  26. Ito T, Ozawa K, Shimada K. Current drug targets and future therapy of pulmonary arterial hypertension. Curr Med Chem. 2007;14(6):719–33.

    Article  PubMed  CAS  Google Scholar 

  27. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425–34.

    PubMed  CAS  Google Scholar 

  28. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart. 2006;92(7):926–32.

    Article  PubMed  CAS  Google Scholar 

  29. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003;23:344–50.

    Article  Google Scholar 

  30. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119–25.

    Article  PubMed  CAS  Google Scholar 

  31. Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomised, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–4.

    PubMed  Google Scholar 

  32. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.

    Article  PubMed  CAS  Google Scholar 

  33. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–23.

    Article  PubMed  CAS  Google Scholar 

  34. Galie N, Hoeper MM, Jansa P, et al. Bosentan improves hemodynamics and delays time to clinical worsening in patients with mildly symptomatic pulmonary arterial hypertension (PAH): results of the EARLY study. Eur Heart J. 2007;28(suppl.1):140. Ref Type: Abstract.

    Google Scholar 

  35. Denton CP, Pope JE, Peter HH, on behalf of the TRacleer Use in PAH associated with Scleroderma and Connective Tissue Diseases (TRUST) Investigators. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008;67:1222–8.

    Article  PubMed  CAS  Google Scholar 

  36. Peter HH, et al. Arthritis Rheum. 2008;58(Suppl):1225.

    Google Scholar 

  37. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47(10):2049–56.

    Article  PubMed  CAS  Google Scholar 

  38. Langleben D, Brock T, Dixon R, Barst R. STRIDE 1: effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol. 2004;44:S80–4.

    Article  PubMed  CAS  Google Scholar 

  39. Oudiz R. Functional class improvement with sitaxsentan in patients with class II-IV pulmonary arterial hypertension (PAH). ATS. 2006; A824.

    Google Scholar 

  40. Siebold J. Sitaxsentan, a selective endothelin-A receptor antagonist, improves exercise capacity in pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD). Chest 2005; A2704.

    Google Scholar 

  41. Highland KB, Strange C, Girgis RE, Black C. Comparison of sitaxentan and bosentan in pulmonary arterial hypertension associated with connective tissue disease [abstract]. Ann Rheum Dis. 2006;65(Suppl II):393.

    Google Scholar 

  42. Valerio CJ, Handler CE, Kabunga P, et al. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension. Rheumatology (Oxford). 2010;49(11):2147–53.

    Article  CAS  Google Scholar 

  43. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–9.

    Article  PubMed  Google Scholar 

  44. Data on file GlaxoSmithKline AMB 029 & 037

    Google Scholar 

  45. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.

    Article  PubMed  CAS  Google Scholar 

  46. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.

    Article  PubMed  Google Scholar 

  47. Simmoneau G, Rubin L, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521–30.

    Google Scholar 

  48. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780–8.

    Article  PubMed  CAS  Google Scholar 

  49. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27:1485–94.

    Article  PubMed  CAS  Google Scholar 

  50. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174:1034–41.

    Article  PubMed  Google Scholar 

  51. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation. 2010;122(2):164–72.

    Article  PubMed  Google Scholar 

  52. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383–94.

    Article  PubMed  Google Scholar 

  53. Condliffe R. Disease progression in systemic sclerosis associated pulmonary hypertension. In: Abraham D et al, editors. Advances in vascular medicine. Part 5. 2010. p. 289–303.

    Google Scholar 

  54. Launay D, Sitbon O, LePavec J, et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology. 2010;49:490–500.

    Article  PubMed  CAS  Google Scholar 

  55. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52(12):3792–800.

    Article  PubMed  Google Scholar 

  56. Montani D, Price C, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Resp J. 2009;33(1):189–200.

    Article  CAS  Google Scholar 

  57. Montani D, Archouch L, Dorfmuller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and haemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicien (Baltimore). 2008;87(4):220–33.

    Article  Google Scholar 

  58. Badesch DB, McGoon MD, Barst RJ, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009;36(10):2244–9.

    Article  PubMed  CAS  Google Scholar 

  59. Kabunga P, et al. Eur Respir J Suppl. 2007;30:250s.

    Google Scholar 

  60. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2008;177(10):1122–7.

    Article  PubMed  Google Scholar 

  61. Hachulla AL, Launay D, Gaxotte V, et al. Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis. 2009;68(12):1878–84.

    Article  PubMed  Google Scholar 

  62. Akram MR, Handler CE, Williams M, et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford). 2006;45(11):1395–8.

    Article  CAS  Google Scholar 

  63. Lam CS, Roger VL, Rodeheffer RJ, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119–26.

    Article  PubMed  Google Scholar 

  64. Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation. 2008;118:2190–9.

    Article  PubMed  Google Scholar 

  65. Townsley MI, Fu Z, Mathieu-Costello O, et al. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res. 1995;77:317–25.

    PubMed  CAS  Google Scholar 

  66. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732–9.

    Article  PubMed  CAS  Google Scholar 

  67. Cooper CJ, Jevnikar FW, Walsh T, et al. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol. 1998;82(5):609–14.

    Article  PubMed  CAS  Google Scholar 

  68. Fawzy M, Osman A, Nambiar V, et al. Immediate and long-term results of mitral balloon valvuloplasty in patients with severe pulmonary hypertension. J Heart Valve Dis. 2008;17:485–91.

    PubMed  Google Scholar 

  69. Nair PK, Kormos RL, Teuteberg JJ, et al. Pulsatile left ventricular assist device support as a bridge to decision in patients with end-stage heart failure complicated by pulmonary hypertension. J Heart Lung Transplant. 2010;29(2):201–8.

    Article  PubMed  Google Scholar 

  70. Drazner MH, Hamilton MA, Fonarow G, et al. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant. 1999;18(11):1126–32.

    Article  PubMed  CAS  Google Scholar 

  71. Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail. 2008;1(4):213–9.

    Article  PubMed  CAS  Google Scholar 

  72. Guazzi M, Tumminello G, Di Marco F, et al. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 2004;44(12):2339–48.

    Article  PubMed  CAS  Google Scholar 

  73. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248–54.

    Article  PubMed  Google Scholar 

  74. Corte TJ, Wort SJ, Gatzoulis MA, et al. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax. 2009;64(10):883–8.

    Article  PubMed  CAS  Google Scholar 

  75. Hoeper MM, Andreas S, Bastian A, et al. Pulmonary hypertension due to chronic lung disease. Recommendations of the Cologne Consensus Conference 2010. Dtsch Med Wochenschr. 2010;135 Suppl 3:S115–24.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Royal Free Hospital, Hampstead, London, UK

    John Gerard Coghlan MD, FRCP

Authors
  1. John Gerard Coghlan MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Gerard Coghlan MD, FRCP .

Editor information

Editors and Affiliations

  1. Feinberg School of Medicine, Northwestern University, E. Huron Street 240, Chicago, 60611-2909, Illinois, USA

    John Varga

  2. Royal Free and University College, Medical School, University College London, Rowland Street, London, NW3 2PF, United Kingdom

    Christopher P. Denton

  3. School of Medicine, Div. Rheumatology, Johns Hopkins University, Eastern Avenue 5200, Baltimore, 21224, Maryland, USA

    Fredrick M. Wigley

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Coghlan, J.G. (2012). Complex Challenges of Pulmonary Hypertension. In: Varga, J., Denton, C., Wigley, F. (eds) Scleroderma. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-5774-0_38

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5774-0_38

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-5773-3

  • Online ISBN: 978-1-4419-5774-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation